Expanding the Business by Using Bioindustry Support as the Revenue and Technology Base
First written in FY2016. 22 of 25 entries say "Restated". Latest entry: FY2025-H1.
0 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
試薬・機器事業とCDMO事業を通じた創薬基盤技術開発およびグローバルプラットフォーマー化の方針を継続している。 - FY2024-Q3RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
試薬・機器事業とCDMO事業を通じた創薬基盤技術開発およびグローバルプラットフォーマー化の方針を継続している。 - FY2024-Q2RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
試薬・機器事業とCDMO事業を通じてバイオ創薬基盤技術を開発し、グローバルプラットフォーマーを目指す方針を継続している。 - FY2024-Q1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2025, ending in fiscal 2025, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and CDMO business, with the aim of becoming a global platform company supporting the infrastructure of the life sciences industry.」
研究用試薬・機器事業とCDMO事業を通じたバイオ創薬基盤技術開発およびグローバルプラットフォーマー化の方針を継続している。 - FY2023AdvancedAnnual report
「Establish a glocal marketing and sales strategy tailored to regional characteristics, including expanding sales of B2B custom products, and target annual growth of 7% on a local-currency basis.」
Sets a specific target for the reagents business of a glocal sales strategy tailored to regional characteristics and 7% annual growth on a local-currency basis. - FY2023-Q3RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
従来のバイオ産業支援の役割を引き継ぐ試薬・機器事業とCDMO事業を通じ、創薬基盤技術と新モダリティを創出する方針を継続している。 - FY2023-Q2RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
従来のバイオ産業支援の役割を引き継ぐ試薬・機器事業とCDMO事業を通じた創薬基盤技術開発の方針を継続している。 - FY2023-Q1RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
従来のバイオ産業支援の役割を引き継ぐ試薬・機器事業とCDMO事業を通じ、創薬基盤技術開発を進める方針を継続している。 - FY2022-Q3RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
従来のバイオ産業支援の役割を引き継ぐ試薬・機器事業と受託事業を通じ、創薬基盤技術開発を進める方針を継続している。 - FY2022-Q2RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
従来のバイオ産業支援の役割を引き継ぐ試薬・機器事業と受託事業を通じた創薬基盤技術開発を継続している。 - FY2022-Q1RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
従来のバイオ産業支援事業の役割を、試薬・機器事業と受託事業を通じたバイオ創薬基盤技術開発へ結び付ける方針を継続している。 - FY2021-Q2RestatedAnnual report
「Under the newly formulated Long-Term Management Vision 2025 and Medium-Term Management Plan 2022, the Group advanced initiatives to develop core biotechnology platforms for drug discovery through its research reagents and scientific instruments business and CDMO business, with the aim of becoming a drug discovery company that continuously creates new modalities.」
研究用試薬・理化学機器事業とCDMO事業を通じた創薬基盤技術開発の位置づけを再掲している。 - FY2021-Q1ReframedAnnual report
「Under the newly formulated Long-Term Management Vision 2025 and Medium-Term Management Plan 2022, the Group advanced initiatives to develop core biotechnology platforms for drug discovery through its research reagents and scientific instruments business and CDMO business, with the aim of becoming a drug discovery company that continuously creates new modalities.」
The role previously described as using Bioindustry Support as an earnings and technology base has been reorganized around developing core biotechnology platforms for drug discovery through the research reagents and scientific instruments business and CDMO business. - FY2020-Q3RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
バイオ産業支援事業をコアビジネスとする位置づけを継続している。 - FY2020-Q2RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
バイオ産業支援事業をコアビジネスとする位置づけを継続している。 - FY2019-Q3RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
バイオ産業支援事業をコアビジネスとする位置づけを継続している。 - FY2019-Q2RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
バイオ産業支援事業をコアビジネスとする位置づけを継続している。 - FY2019-Q1RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
バイオ産業支援事業をコアビジネスとする位置づけを継続している。 - FY2018-Q3RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
バイオ産業支援事業をコアビジネスとする位置づけを継続している。 - FY2018-Q2RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
バイオ産業支援事業をコアビジネスとする位置づけを継続している。 - FY2018-Q1RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
Reaffirms the positioning of the Bioindustry Support Business as the core business. - FY2017-Q3RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
Reaffirms the positioning of the Bioindustry Support Business as the core business. - FY2017-Q2RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
Reaffirms the positioning of the Bioindustry Support Business as the core business. - FY2017-Q1RestatedAnnual report
「As research and development activities in biotechnology-related fields continue to expand, the Group positions this business, which focuses on products, goods and services supporting such activities, as its core business.」
Reaffirms the positioning of the Bioindustry Support Business as the core business. - FY2016First statedAnnual report
「The Bioindustry Support Business is the Group’s current core business and earnings base, as well as its technology base for expansion into other businesses. While establishing this business as a stable source of earnings, the Group is working to develop the Medical Food and Biotechnology Business as its second earnings business. Going forward, it plans to prioritize investment of cash flow generated by other businesses in the Gene Medicine Business and expand operations from research support into food and then medical fields.」
Presents a strategy of using the existing Bioindustry Support Business as an earnings source and technology base, developing the Medical Food and Biotechnology Business, and directing funds toward gene medicine.